CGONCG Oncology, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $4M
- 255% YoY
- Operating margin
- -4722.1%
- 53% YoY
- EBITDA
- −$189M
- 65% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$17M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired660% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear1% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $204K | $1M | $4M | 255% |
| Operating income | −$55M | −$115M | −$191M | 66% |
| Net income | −$49M | −$88M | −$161M | 83% |
| Operating cash flow | −$46M | −$79M | −$132M | 68% |
| Capex | — | $234K | $134K | 43% |
| Stock-based comp | $2M | $11M | $27M | 134% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $135K · 3
- Net
- −$135K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $12M | $29M | 112 | 131 |
| FY2024 | $11M | $23M | 77 | 98 |